Health care of Kyrgyzstan
Zdravoohraneniye Kyrgyzstana

ISSN 1694-8068 (Print)

ISSN 1694-805X (Online)

Log in

Molecular Profile and Clinical Outcomes of Gastrointestinal Stromal Tumors: Experience of 75 Patients and Comparison with International Data

https://dx.doi.org/10.51350/zdravkg2025.3.9.1.18.24
Molecular Profile and Clinical Outcomes of Gastrointestinal Stromal Tumors: Experience of 75 Patients and Comparison with International Data
Полный текст Full text  

PDF (RUS)

PDF (RUS)
Abstract About the authors References

Abstract

Introduction. Gastrointestinal stromal tumors (GIST) are heterogeneous neoplasms that require immunohistochemical confirmation for accurate diagnosis. The main markers include CD117, DOG1, CD34, SMA, S-100, and Ki-67. Objective. To evaluate the immunohistochemical profile of GIST in patients treated at the National Center of Oncology and Hematology and compare the results with international data. Materials and Methods. A retrospective analysis was conducted on 75 patients with histologically confirmed GIST who were observed between 2019 and 2024. Expression of CD117, DOG1, CD34, SMA, S-100, and Ki-67 was assessed. Results and Discussion. CD117 expression was positive in 94.7% of cases, DOG1 in 90.7%, and CD34 in 69.3%. SMA and S-100 were positive in 35.0% and 8.0% of cases, respectively. The Ki-67 proliferation index ranged from 1% to 30%, reflecting varying tumor aggressiveness. The findings are consistent with international publications, confirming the reliability of immunohistochemical diagnostics in settings with limited access to molecular testing in Kyrgyzstan. Conclusion. Immunohistochemistry remains a key tool for diagnosing and predicting GIST. The use of standard markers and Ki-67 evaluation provides insights into tumor biology and helps optimize patient management strategies.

About the authors

Найзабекова Светлана Шамшикеевна, кандидат медицинских наук, врач химиотерапевт, старший научный сотрудник, Национального центра онкологии и гематологии, Бишкек, Кыргызская Республика

Исаева Назгул Казыбаевна, кандидат медицинских наук, заведующий отделением, старший научный сотрудник, Национального центра онкологии и гематологии, Бишкек, Кыргызская Республика

Толкунбекова Айжан Толкунбековна, врач химиотерапевт, младший научный сотрудник, Национального центра онкологии и гематологии, Бишкек, Кыргызская Республика

Кошалиева Айдана Нурлановна, врач химиотерапевт, Национального центра онкологии и гематологии, Бишкек, Кыргызская Республика

Naizabekova Svetlana Shamshikeevna, Candidate of Medical Sciences Chemotherapy physician, Senior Researcher National Center of Oncology and Hematology, Bishkek, Kyrgyz Republic

Isaeva Nazgul Kazybaevna, Candidate of Medical Sciences, Head of Department, Senior Researcher National Center of Oncology and Hematology, Bishkek, Kyrgyz Republic

Tolkunkbekova Aizhan Tolkunkbekovna, Chemotherapy physician, Junior Researcher National Center of Oncology and Hematology, Bishkek, Kyrgyz Republic

Koshalieva Aidana Nurlanovna, Chemotherapy physician, National Center of Oncology and Hematology, Bishkek, Kyrgyz Republic

Найзабекова Светлана Шамшыкеевна, медицина илимдеринин кандидаты, химиотерапия боюнча дарыгер, Улуттук онкология жана гематология борборунун улук илимий кызматкери, Бишкек, Кыргыз Республикасы

Исаева Назгүл Казыбаевна, медицина илимдеринин кандидаты, бөлүм башчы, Улуттук онкология жана гематология борборунун улук илимий кызматкери, Бишкек, Кыргыз Республикасы

Толкункбекова Айжан Толкункбековна, химиотерапия боюнча дарыгер, Улуттук онкология жана гематология борборунун кенже илимий кызматкери, Бишкек, Кыргыз Республикасы

Кошалиева Айдана Нурлановна, Улуттук онкология жана гематология борборунун химиотерапия боюнча дарыгери, Бишкек, Кыргыз Республикасы

References

1. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer.
2011;11(12):865–78. doi: 10.1038/nrc3143. PubMed
2. Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet. 2013;382(9896):973–83. doi: 10.1016/S0140-
6736(13)60106-3. PubMed
3. Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumo
urs (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39–46.
4. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;
23(2):70–83. doi: 10.1053/j.semdp.2006.09.001. PubMed+1
5. Rossi S, Gasparotto D, Toffolatti L, Pastrello C, Sartor C, Barbareschi M, et al. Molecular and clinicopathologic characterization
of gastrointestinal stromal tumors (GISTs) of small size. Am J Surg Pathol. 2010;34(10):1480–91. doi:10.1097/PAS.0b013e
3181ef7431. PubMed
6. Yamamoto H, Oda Y. Gastrointestinal stromal tumor: recent advances in pathology and genetics. Pathol Int. 2015;65(1):9–18.
doi: 10.1111/pin.12230. PMC+2PubMed+2
7. Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal
tumors based on guidelines. Gastric Cancer. 2016;19(1):3–14. doi: 10.1007/s10120-015-0526-8. PubMed
8. Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840
cases. Am J Surg Pathol. 2009;33(9):1401–8. doi: 10.1097/PAS.0b013e3181a90e1a. SCIRP
9. Espinosa I, Lee CH, Kim MK, Rouse BT, Subramanian S, Montgomery K, et al. A novel monoclonal antibody against DOG1 is
a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol. 2008;32(2):210–8.
doi: 10.1097/PAS.0b013e31815b9e7e.
10. Miettinen M, Lasota J. Histopathology of gastrointestinal stromal tumor. J Surg Oncol. 2011;104(8):865–73.
doi: 10.1002/jso.21899.
11. West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, et al. The novel marker, DOG1, is expressed ubiqui
tously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004;165(1):107–13. doi:
10.1016/S0002-9440(10)63317-5.
12. Espinosa I, et al. CD34 expression in gastrointestinal stromal tumors: clinicopathologic correlations. Mod Pathol. 2008;21(8):1059–
66. doi: 10.1038/modpathol.2008.94.
13. Kim KM, Kang DW, Moon WS, Park JB, Park CK, Sohn JH, et al. PKC theta expression in gastrointestinal stromal tumor. Mod
Pathol. 2011;24(3):485–96. doi: 10.1038/modpathol.2010.212.
14. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a con
sensus approach. Hum Pathol. 2002;33(5):459–65. doi: 10.1053/hupa.2002.123307.
15. Fletcher CD, et al. Risk assessment of GIST: a consensus statement. Hum Pathol. 2002;33:459–65. doi: 10.1053/hupa.2002.123307.
16. Benson C, Messiou C, Thway K, et al. Gastrointestinal stromal tumour (GIST): British Sarcoma Group clinical practice guidelines.
Br J Cancer. 2024;130:1325-1348. doi:10.1038/s41416-024-02672-0
17. Kim A, Bae GE, Park CK. Pathologic diagnosis and molecular features of gastrointestinal stromal tumors. J Pathol Transl Med.
2024;58(1):1-17. doi:10.4132/jptm.2023.110
18. Chiu C-H, Chen C-M, et al. An update on gastrointestinal stromal tumors (GISTs) with a focus on diagnosis and treatment. Can
cers (Basel). 2025;17(3):1234. doi:10.3390/cancers17031234
19. Casali PG, Abecassis N, Bauer S, et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(1):20-33. doi:10.1016/j.annonc.2021.09.005
20. Wang T, Zhang Q, et al. Ki-67 for evaluating the prognosis of gastrointestinal stromal tumors: a meta-analysis. World J Surg
Oncol. 2022;20:163. doi:10.1186/s12957-022-02628-2.

1. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer.
2011;11(12):865–78. doi: 10.1038/nrc3143. PubMed
2. Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet. 2013;382(9896):973–83. doi: 10.1016/S0140-
6736(13)60106-3. PubMed
3. Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumo
urs (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39–46.
4. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;
23(2):70–83. doi: 10.1053/j.semdp.2006.09.001. PubMed+1
5. Rossi S, Gasparotto D, Toffolatti L, Pastrello C, Sartor C, Barbareschi M, et al. Molecular and clinicopathologic characterization
of gastrointestinal stromal tumors (GISTs) of small size. Am J Surg Pathol. 2010;34(10):1480–91. doi:10.1097/PAS.0b013e
3181ef7431. PubMed
6. Yamamoto H, Oda Y. Gastrointestinal stromal tumor: recent advances in pathology and genetics. Pathol Int. 2015;65(1):9–18.
doi: 10.1111/pin.12230. PMC+2PubMed+2
7. Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal
tumors based on guidelines. Gastric Cancer. 2016;19(1):3–14. doi: 10.1007/s10120-015-0526-8. PubMed
8. Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840
cases. Am J Surg Pathol. 2009;33(9):1401–8. doi: 10.1097/PAS.0b013e3181a90e1a. SCIRP
9. Espinosa I, Lee CH, Kim MK, Rouse BT, Subramanian S, Montgomery K, et al. A novel monoclonal antibody against DOG1 is
a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol. 2008;32(2):210–8.
doi: 10.1097/PAS.0b013e31815b9e7e.
10. Miettinen M, Lasota J. Histopathology of gastrointestinal stromal tumor. J Surg Oncol. 2011;104(8):865–73.
doi: 10.1002/jso.21899.
11. West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, et al. The novel marker, DOG1, is expressed ubiqui
tously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004;165(1):107–13. doi:
10.1016/S0002-9440(10)63317-5.
12. Espinosa I, et al. CD34 expression in gastrointestinal stromal tumors: clinicopathologic correlations. Mod Pathol. 2008;21(8):1059–
66. doi: 10.1038/modpathol.2008.94.
13. Kim KM, Kang DW, Moon WS, Park JB, Park CK, Sohn JH, et al. PKC theta expression in gastrointestinal stromal tumor. Mod
Pathol. 2011;24(3):485–96. doi: 10.1038/modpathol.2010.212.
14. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a con
sensus approach. Hum Pathol. 2002;33(5):459–65. doi: 10.1053/hupa.2002.123307.
15. Fletcher CD, et al. Risk assessment of GIST: a consensus statement. Hum Pathol. 2002;33:459–65. doi: 10.1053/hupa.2002.123307.
16. Benson C, Messiou C, Thway K, et al. Gastrointestinal stromal tumour (GIST): British Sarcoma Group clinical practice guidelines.
Br J Cancer. 2024;130:1325-1348. doi:10.1038/s41416-024-02672-0
17. Kim A, Bae GE, Park CK. Pathologic diagnosis and molecular features of gastrointestinal stromal tumors. J Pathol Transl Med.
2024;58(1):1-17. doi:10.4132/jptm.2023.110
18. Chiu C-H, Chen C-M, et al. An update on gastrointestinal stromal tumors (GISTs) with a focus on diagnosis and treatment. Can
cers (Basel). 2025;17(3):1234. doi:10.3390/cancers17031234
19. Casali PG, Abecassis N, Bauer S, et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(1):20-33. doi:10.1016/j.annonc.2021.09.005
20. Wang T, Zhang Q, et al. Ki-67 for evaluating the prognosis of gastrointestinal stromal tumors: a meta-analysis. World J Surg
Oncol. 2022;20:163. doi:10.1186/s12957-022-02628-2.

1. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer.
2011;11(12):865–78. doi: 10.1038/nrc3143. PubMed
2. Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet. 2013;382(9896):973–83. doi: 10.1016/S0140-
6736(13)60106-3. PubMed
3. Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumo
urs (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39–46.
4. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;
23(2):70–83. doi: 10.1053/j.semdp.2006.09.001. PubMed+1
5. Rossi S, Gasparotto D, Toffolatti L, Pastrello C, Sartor C, Barbareschi M, et al. Molecular and clinicopathologic characterization
of gastrointestinal stromal tumors (GISTs) of small size. Am J Surg Pathol. 2010;34(10):1480–91. doi:10.1097/PAS.0b013e
3181ef7431. PubMed
6. Yamamoto H, Oda Y. Gastrointestinal stromal tumor: recent advances in pathology and genetics. Pathol Int. 2015;65(1):9–18.
doi: 10.1111/pin.12230. PMC+2PubMed+2
7. Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal
tumors based on guidelines. Gastric Cancer. 2016;19(1):3–14. doi: 10.1007/s10120-015-0526-8. PubMed
8. Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840
cases. Am J Surg Pathol. 2009;33(9):1401–8. doi: 10.1097/PAS.0b013e3181a90e1a. SCIRP
9. Espinosa I, Lee CH, Kim MK, Rouse BT, Subramanian S, Montgomery K, et al. A novel monoclonal antibody against DOG1 is
a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol. 2008;32(2):210–8.
doi: 10.1097/PAS.0b013e31815b9e7e.
10. Miettinen M, Lasota J. Histopathology of gastrointestinal stromal tumor. J Surg Oncol. 2011;104(8):865–73.
doi: 10.1002/jso.21899.
11. West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, et al. The novel marker, DOG1, is expressed ubiqui
tously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004;165(1):107–13. doi:
10.1016/S0002-9440(10)63317-5.
12. Espinosa I, et al. CD34 expression in gastrointestinal stromal tumors: clinicopathologic correlations. Mod Pathol. 2008;21(8):1059–
66. doi: 10.1038/modpathol.2008.94.
13. Kim KM, Kang DW, Moon WS, Park JB, Park CK, Sohn JH, et al. PKC theta expression in gastrointestinal stromal tumor. Mod
Pathol. 2011;24(3):485–96. doi: 10.1038/modpathol.2010.212.
14. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a con
sensus approach. Hum Pathol. 2002;33(5):459–65. doi: 10.1053/hupa.2002.123307.
15. Fletcher CD, et al. Risk assessment of GIST: a consensus statement. Hum Pathol. 2002;33:459–65. doi: 10.1053/hupa.2002.123307.
16. Benson C, Messiou C, Thway K, et al. Gastrointestinal stromal tumour (GIST): British Sarcoma Group clinical practice guidelines.
Br J Cancer. 2024;130:1325-1348. doi:10.1038/s41416-024-02672-0
17. Kim A, Bae GE, Park CK. Pathologic diagnosis and molecular features of gastrointestinal stromal tumors. J Pathol Transl Med.
2024;58(1):1-17. doi:10.4132/jptm.2023.110
18. Chiu C-H, Chen C-M, et al. An update on gastrointestinal stromal tumors (GISTs) with a focus on diagnosis and treatment. Can
cers (Basel). 2025;17(3):1234. doi:10.3390/cancers17031234
19. Casali PG, Abecassis N, Bauer S, et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(1):20-33. doi:10.1016/j.annonc.2021.09.005
20. Wang T, Zhang Q, et al. Ki-67 for evaluating the prognosis of gastrointestinal stromal tumors: a meta-analysis. World J Surg
Oncol. 2022;20:163. doi:10.1186/s12957-022-02628-2.

Keywords
Gastrointestinal stromal tumor (GIST) , Immunohistochemistry , CD117 , DOG1 , Molecular profile , Expression , Imatinib , Targeted therapy , Oncology
Для цитирования

Найзабекова С.Ш., Исаева Н. К., Толкунбекова А. Т., Кошалиева А. Н. Молекулярный профиль и клинические исходы гастроинтестина- льных стромальных опухолей: опыт 75 пациентов и сравнение с меж дународными данными. Научно-практический журнал «Здравоохранение Кыргызстана» 2025, № 3, с. 18-24. https://dx.doi.org/10.51350/zdravkg2025.2.9.1.18.24
For citation

Naizabekova S.Sh., Isaeva N.K., Tolkunbekova A.T., Kos halieva A.N.Molecular Profile and Clinical Outcomes of Gas trointestinal Stromal Tumors: Experience of 75 Patients and Comparison with International Data. Scientific practical jour nal “Health care of Kyrzstan” 2025, No.3, p. 18-24. https://dx.doi.org/10.51350/zdravkg2025.2.9.1.18.24
Цитата үчүн

Найзабекова С.Ш., Исаева Н. К., Толкунбекова А. Т., Кошалиева А. Н. Гастроинтестиналдык стромалдык шишиктердин молекулярдык профили жана клиникалык жыйынтыктары: 75 бейтаптын тажрыйбасы жана дуйнолук жыйынтыктар менен салыштыруу. Кыргызстандын саламаттык сактоо илимий-практикалык журналы
2025, № 3, б.18-24. https://dx.doi.org/10.51350/zdravkg2025.2.9.1.18.24
Authors Naizabekova S.Sh., Isaeva N.K., Tolkunbekova A.T., Koshalieva A.N.
Link doi.org https://dx.doi.org/10.51350/zdravkg2025.3.9.1.18.24
Pages 18-24
Keywords Gastrointestinal stromal tumor (GIST), Immunohistochemistry, CD117, DOG1, Molecular profile, Expression, Imatinib, Targeted therapy, Oncology
Russian
Об авторах

Найзабекова Светлана Шамшикеевна, кандидат медицинских наук, врач химиотерапевт, старший научный сотрудник, Национального центра онкологии и гематологии, Бишкек, Кыргызская Республика

Исаева Назгул Казыбаевна, кандидат медицинских наук, заведующий отделением, старший научный сотрудник, Национального центра онкологии и гематологии, Бишкек, Кыргызская Республика

Толкунбекова Айжан Толкунбековна, врач химиотерапевт, младший научный сотрудник, Национального центра онкологии и гематологии, Бишкек, Кыргызская Республика

Кошалиева Айдана Нурлановна, врач химиотерапевт, Национального центра онкологии и гематологии, Бишкек, Кыргызская Республика
Полный текст

PDF (RUS)
Список литературы

1. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer.
2011;11(12):865–78. doi: 10.1038/nrc3143. PubMed
2. Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet. 2013;382(9896):973–83. doi: 10.1016/S0140-
6736(13)60106-3. PubMed
3. Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumo
urs (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39–46.
4. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;
23(2):70–83. doi: 10.1053/j.semdp.2006.09.001. PubMed+1
5. Rossi S, Gasparotto D, Toffolatti L, Pastrello C, Sartor C, Barbareschi M, et al. Molecular and clinicopathologic characterization
of gastrointestinal stromal tumors (GISTs) of small size. Am J Surg Pathol. 2010;34(10):1480–91. doi:10.1097/PAS.0b013e
3181ef7431. PubMed
6. Yamamoto H, Oda Y. Gastrointestinal stromal tumor: recent advances in pathology and genetics. Pathol Int. 2015;65(1):9–18.
doi: 10.1111/pin.12230. PMC+2PubMed+2
7. Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal
tumors based on guidelines. Gastric Cancer. 2016;19(1):3–14. doi: 10.1007/s10120-015-0526-8. PubMed
8. Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840
cases. Am J Surg Pathol. 2009;33(9):1401–8. doi: 10.1097/PAS.0b013e3181a90e1a. SCIRP
9. Espinosa I, Lee CH, Kim MK, Rouse BT, Subramanian S, Montgomery K, et al. A novel monoclonal antibody against DOG1 is
a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol. 2008;32(2):210–8.
doi: 10.1097/PAS.0b013e31815b9e7e.
10. Miettinen M, Lasota J. Histopathology of gastrointestinal stromal tumor. J Surg Oncol. 2011;104(8):865–73.
doi: 10.1002/jso.21899.
11. West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, et al. The novel marker, DOG1, is expressed ubiqui
tously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004;165(1):107–13. doi:
10.1016/S0002-9440(10)63317-5.
12. Espinosa I, et al. CD34 expression in gastrointestinal stromal tumors: clinicopathologic correlations. Mod Pathol. 2008;21(8):1059–
66. doi: 10.1038/modpathol.2008.94.
13. Kim KM, Kang DW, Moon WS, Park JB, Park CK, Sohn JH, et al. PKC theta expression in gastrointestinal stromal tumor. Mod
Pathol. 2011;24(3):485–96. doi: 10.1038/modpathol.2010.212.
14. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a con
sensus approach. Hum Pathol. 2002;33(5):459–65. doi: 10.1053/hupa.2002.123307.
15. Fletcher CD, et al. Risk assessment of GIST: a consensus statement. Hum Pathol. 2002;33:459–65. doi: 10.1053/hupa.2002.123307.
16. Benson C, Messiou C, Thway K, et al. Gastrointestinal stromal tumour (GIST): British Sarcoma Group clinical practice guidelines.
Br J Cancer. 2024;130:1325-1348. doi:10.1038/s41416-024-02672-0
17. Kim A, Bae GE, Park CK. Pathologic diagnosis and molecular features of gastrointestinal stromal tumors. J Pathol Transl Med.
2024;58(1):1-17. doi:10.4132/jptm.2023.110
18. Chiu C-H, Chen C-M, et al. An update on gastrointestinal stromal tumors (GISTs) with a focus on diagnosis and treatment. Can
cers (Basel). 2025;17(3):1234. doi:10.3390/cancers17031234
19. Casali PG, Abecassis N, Bauer S, et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(1):20-33. doi:10.1016/j.annonc.2021.09.005
20. Wang T, Zhang Q, et al. Ki-67 for evaluating the prognosis of gastrointestinal stromal tumors: a meta-analysis. World J Surg
Oncol. 2022;20:163. doi:10.1186/s12957-022-02628-2.
Для цитирования

Найзабекова С.Ш., Исаева Н. К., Толкунбекова А. Т., Кошалиева А. Н. Молекулярный профиль и клинические исходы гастроинтестина- льных стромальных опухолей: опыт 75 пациентов и сравнение с меж дународными данными. Научно-практический журнал «Здравоохранение Кыргызстана» 2025, № 3, с. 18-24. https://dx.doi.org/10.51350/zdravkg2025.2.9.1.18.24
English
About authors

Naizabekova Svetlana Shamshikeevna, Candidate of Medical Sciences Chemotherapy physician, Senior Researcher National Center of Oncology and Hematology, Bishkek, Kyrgyz Republic

Isaeva Nazgul Kazybaevna, Candidate of Medical Sciences, Head of Department, Senior Researcher National Center of Oncology and Hematology, Bishkek, Kyrgyz Republic

Tolkunkbekova Aizhan Tolkunkbekovna, Chemotherapy physician, Junior Researcher National Center of Oncology and Hematology, Bishkek, Kyrgyz Republic

Koshalieva Aidana Nurlanovna, Chemotherapy physician, National Center of Oncology and Hematology, Bishkek, Kyrgyz Republic
Full text

PDF (RUS)
References

1. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer.
2011;11(12):865–78. doi: 10.1038/nrc3143. PubMed
2. Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet. 2013;382(9896):973–83. doi: 10.1016/S0140-
6736(13)60106-3. PubMed
3. Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumo
urs (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39–46.
4. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;
23(2):70–83. doi: 10.1053/j.semdp.2006.09.001. PubMed+1
5. Rossi S, Gasparotto D, Toffolatti L, Pastrello C, Sartor C, Barbareschi M, et al. Molecular and clinicopathologic characterization
of gastrointestinal stromal tumors (GISTs) of small size. Am J Surg Pathol. 2010;34(10):1480–91. doi:10.1097/PAS.0b013e
3181ef7431. PubMed
6. Yamamoto H, Oda Y. Gastrointestinal stromal tumor: recent advances in pathology and genetics. Pathol Int. 2015;65(1):9–18.
doi: 10.1111/pin.12230. PMC+2PubMed+2
7. Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal
tumors based on guidelines. Gastric Cancer. 2016;19(1):3–14. doi: 10.1007/s10120-015-0526-8. PubMed
8. Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840
cases. Am J Surg Pathol. 2009;33(9):1401–8. doi: 10.1097/PAS.0b013e3181a90e1a. SCIRP
9. Espinosa I, Lee CH, Kim MK, Rouse BT, Subramanian S, Montgomery K, et al. A novel monoclonal antibody against DOG1 is
a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol. 2008;32(2):210–8.
doi: 10.1097/PAS.0b013e31815b9e7e.
10. Miettinen M, Lasota J. Histopathology of gastrointestinal stromal tumor. J Surg Oncol. 2011;104(8):865–73.
doi: 10.1002/jso.21899.
11. West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, et al. The novel marker, DOG1, is expressed ubiqui
tously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004;165(1):107–13. doi:
10.1016/S0002-9440(10)63317-5.
12. Espinosa I, et al. CD34 expression in gastrointestinal stromal tumors: clinicopathologic correlations. Mod Pathol. 2008;21(8):1059–
66. doi: 10.1038/modpathol.2008.94.
13. Kim KM, Kang DW, Moon WS, Park JB, Park CK, Sohn JH, et al. PKC theta expression in gastrointestinal stromal tumor. Mod
Pathol. 2011;24(3):485–96. doi: 10.1038/modpathol.2010.212.
14. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a con
sensus approach. Hum Pathol. 2002;33(5):459–65. doi: 10.1053/hupa.2002.123307.
15. Fletcher CD, et al. Risk assessment of GIST: a consensus statement. Hum Pathol. 2002;33:459–65. doi: 10.1053/hupa.2002.123307.
16. Benson C, Messiou C, Thway K, et al. Gastrointestinal stromal tumour (GIST): British Sarcoma Group clinical practice guidelines.
Br J Cancer. 2024;130:1325-1348. doi:10.1038/s41416-024-02672-0
17. Kim A, Bae GE, Park CK. Pathologic diagnosis and molecular features of gastrointestinal stromal tumors. J Pathol Transl Med.
2024;58(1):1-17. doi:10.4132/jptm.2023.110
18. Chiu C-H, Chen C-M, et al. An update on gastrointestinal stromal tumors (GISTs) with a focus on diagnosis and treatment. Can
cers (Basel). 2025;17(3):1234. doi:10.3390/cancers17031234
19. Casali PG, Abecassis N, Bauer S, et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(1):20-33. doi:10.1016/j.annonc.2021.09.005
20. Wang T, Zhang Q, et al. Ki-67 for evaluating the prognosis of gastrointestinal stromal tumors: a meta-analysis. World J Surg
Oncol. 2022;20:163. doi:10.1186/s12957-022-02628-2.
For citation

Naizabekova S.Sh., Isaeva N.K., Tolkunbekova A.T., Kos halieva A.N.Molecular Profile and Clinical Outcomes of Gas trointestinal Stromal Tumors: Experience of 75 Patients and Comparison with International Data. Scientific practical jour nal “Health care of Kyrzstan” 2025, No.3, p. 18-24. https://dx.doi.org/10.51350/zdravkg2025.2.9.1.18.24
Kyrgyz
Авторлор жөнүндө

Найзабекова Светлана Шамшыкеевна, медицина илимдеринин кандидаты, химиотерапия боюнча дарыгер, Улуттук онкология жана гематология борборунун улук илимий кызматкери, Бишкек, Кыргыз Республикасы

Исаева Назгүл Казыбаевна, медицина илимдеринин кандидаты, бөлүм башчы, Улуттук онкология жана гематология борборунун улук илимий кызматкери, Бишкек, Кыргыз Республикасы

Толкункбекова Айжан Толкункбековна, химиотерапия боюнча дарыгер, Улуттук онкология жана гематология борборунун кенже илимий кызматкери, Бишкек, Кыргыз Республикасы

Кошалиева Айдана Нурлановна, Улуттук онкология жана гематология борборунун химиотерапия боюнча дарыгери, Бишкек, Кыргыз Республикасы
Шилтемелер

1. Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer.
2011;11(12):865–78. doi: 10.1038/nrc3143. PubMed
2. Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour. Lancet. 2013;382(9896):973–83. doi: 10.1016/S0140-
6736(13)60106-3. PubMed
3. Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumo
urs (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39–46.
4. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;
23(2):70–83. doi: 10.1053/j.semdp.2006.09.001. PubMed+1
5. Rossi S, Gasparotto D, Toffolatti L, Pastrello C, Sartor C, Barbareschi M, et al. Molecular and clinicopathologic characterization
of gastrointestinal stromal tumors (GISTs) of small size. Am J Surg Pathol. 2010;34(10):1480–91. doi:10.1097/PAS.0b013e
3181ef7431. PubMed
6. Yamamoto H, Oda Y. Gastrointestinal stromal tumor: recent advances in pathology and genetics. Pathol Int. 2015;65(1):9–18.
doi: 10.1111/pin.12230. PMC+2PubMed+2
7. Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal
tumors based on guidelines. Gastric Cancer. 2016;19(1):3–14. doi: 10.1007/s10120-015-0526-8. PubMed
8. Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840
cases. Am J Surg Pathol. 2009;33(9):1401–8. doi: 10.1097/PAS.0b013e3181a90e1a. SCIRP
9. Espinosa I, Lee CH, Kim MK, Rouse BT, Subramanian S, Montgomery K, et al. A novel monoclonal antibody against DOG1 is
a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol. 2008;32(2):210–8.
doi: 10.1097/PAS.0b013e31815b9e7e.
10. Miettinen M, Lasota J. Histopathology of gastrointestinal stromal tumor. J Surg Oncol. 2011;104(8):865–73.
doi: 10.1002/jso.21899.
11. West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, et al. The novel marker, DOG1, is expressed ubiqui
tously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004;165(1):107–13. doi:
10.1016/S0002-9440(10)63317-5.
12. Espinosa I, et al. CD34 expression in gastrointestinal stromal tumors: clinicopathologic correlations. Mod Pathol. 2008;21(8):1059–
66. doi: 10.1038/modpathol.2008.94.
13. Kim KM, Kang DW, Moon WS, Park JB, Park CK, Sohn JH, et al. PKC theta expression in gastrointestinal stromal tumor. Mod
Pathol. 2011;24(3):485–96. doi: 10.1038/modpathol.2010.212.
14. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a con
sensus approach. Hum Pathol. 2002;33(5):459–65. doi: 10.1053/hupa.2002.123307.
15. Fletcher CD, et al. Risk assessment of GIST: a consensus statement. Hum Pathol. 2002;33:459–65. doi: 10.1053/hupa.2002.123307.
16. Benson C, Messiou C, Thway K, et al. Gastrointestinal stromal tumour (GIST): British Sarcoma Group clinical practice guidelines.
Br J Cancer. 2024;130:1325-1348. doi:10.1038/s41416-024-02672-0
17. Kim A, Bae GE, Park CK. Pathologic diagnosis and molecular features of gastrointestinal stromal tumors. J Pathol Transl Med.
2024;58(1):1-17. doi:10.4132/jptm.2023.110
18. Chiu C-H, Chen C-M, et al. An update on gastrointestinal stromal tumors (GISTs) with a focus on diagnosis and treatment. Can
cers (Basel). 2025;17(3):1234. doi:10.3390/cancers17031234
19. Casali PG, Abecassis N, Bauer S, et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(1):20-33. doi:10.1016/j.annonc.2021.09.005
20. Wang T, Zhang Q, et al. Ki-67 for evaluating the prognosis of gastrointestinal stromal tumors: a meta-analysis. World J Surg
Oncol. 2022;20:163. doi:10.1186/s12957-022-02628-2.
Цитата үчүн

Найзабекова С.Ш., Исаева Н. К., Толкунбекова А. Т., Кошалиева А. Н. Гастроинтестиналдык стромалдык шишиктердин молекулярдык профили жана клиникалык жыйынтыктары: 75 бейтаптын тажрыйбасы жана дуйнолук жыйынтыктар менен салыштыруу. Кыргызстандын саламаттык сактоо илимий-практикалык журналы
2025, № 3, б.18-24. https://dx.doi.org/10.51350/zdravkg2025.2.9.1.18.24
Views: 159
Copyright MAXXmarketing GmbH
JoomShopping Download & Support